SciELO - Scientific Electronic Library Online

 
vol.61 issue3Neurogenic etiology in patients with erectile dysfunctionBellini duct carcinoma: Report of two cases author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Archivos Españoles de Urología (Ed. impresa)

Print version ISSN 0004-0614

Abstract

CANDEBAT MONTERO, L. H. et al. Peyronie's disease: treatment with interferon and laser. Arch. Esp. Urol. [online]. 2008, vol.61, n.3, pp.413-423. ISSN 0004-0614.

Objectives: To evaluate comparatively the results of treatment with interferon, laser and their association in a group of patients with Peyronie’s disease. Methods: We performed an experimental study to evaluate the main results of the treatment of Peyronie’s disease with interferon and laser, at Hospital Provincial Universitario "Saturnino Lora Torres" and Hospital General Universitario "Dr. Juan Bruno Zayas Alfonso" in the city of Santiago de Cuba from January 2003 to July 2005. Ninety-six patients were included, divided into three treatment groups: interferon, laser and interferon plus laser. After initial evaluation, treatment was started and continued for 28 weeks, with reevaluation six and 12 months after the end of treatment. Results: Final results with combined interferon and laser were: symptoms improvement 84.7%, decrease of the size of the fibrous plaque 90.6% and decrease of penile curvature 87.5%. Conclusions: The combination of both therapies resulted to be more effective than each of them separately, so the recommendation is to incorporate it as another therapeutic alternative in Peyronie’s disease.

Keywords : Peyronie’s disease; Interferon; Laser.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License